The estimated Net Worth of Michael Ferraresso is at least $125 Tisíc dollars as of 10 August 2021. Mr Ferraresso owns over 2,608 units of AVEO Pharmaceuticals Inc stock worth over $124,770 and over the last 3 years he sold AVEO stock worth over $0.
Mr has made over 1 trades of the AVEO Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 2,608 units of AVEO stock worth $14,996 on 10 August 2021.
The largest trade he's ever made was buying 2,608 units of AVEO Pharmaceuticals Inc stock on 10 August 2021 worth over $14,996. On average, Mr trades about 869 units every 0 days since 2021. As of 10 August 2021 he still owns at least 8,318 units of AVEO Pharmaceuticals Inc stock.
You can see the complete history of Mr Ferraresso stock trades at the bottom of the page.
Michael Ferraresso is the Chief Commercial Officer at AVEO Pharmaceuticals Inc.
Mr Ferraresso is 47, he's been the Chief Commercial Officer of AVEO Pharmaceuticals Inc since . There are 12 older and 1 younger executives at AVEO Pharmaceuticals Inc. The oldest executive at AVEO Pharmaceuticals Inc is Robert Young, 80, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON, MA, 02108.
Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over $6,664,465 worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth $217,351,881 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $9,488,415. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth $1,248,124.
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include: